FDA Authorizes Pfizer Booster COVID Shot for Children Between the Ages of 5 and 11
Today (May 17, 2022), the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) and authorized a booster dose of the Pfizer-BioNTech COVID-19 shot for children 5 through 11 years of age. The booster shot is 10 micrograms, which is the same dosage for this age group in their primary series and a third of that given to people aged 12 and older. Research shows that there is no benefit to children receiving a COVID shot, and in fact, the shots can cause potential harm, adverse effects and death. According to Pfizer’s own study trial data, the chance of death in children from the shot is 107 times higher than death from COVID. In fact, the CDC recently reported higher COVID-19 case rates have been recorded among fully vaccinated children than unvaccinated in the age group 5-11 since February 2022. That’s the first time CDC recorded a higher case rate among fully vaccinated young children since data was first collected in December 2021. In addition, the Office for National Statistics revealed that children are up to 52 times more likely to die following the COVID-19 injection than children who have not received it. In December 2021, the Office for National Statistics (ONS) published a dataset containing details on “deaths by vaccination status in England” per 100,000 people between January 1, 2021 and Oct 31, 2021. The data revealed that vaccinated children aged 10-14 were statistically 10 times more likely to die than unvaccinated children, and vaccinated teenagers aged 15-19 were statistically two times more likely to die than unvaccinated teenagers.